TY - JOUR
T1 - Preclinical in vivo-models to investigate HIPEC; current methodologies and challenges
AU - Helderman, Roxan F. C. P. A.
AU - Löke, Daan R.
AU - Tanis, Pieter J.
AU - Tuynman, Jurriaan B.
AU - Ceelen, Wim
AU - de Hingh, Ignace H.
AU - van der Speeten, Kurt
AU - Franken, Nicolaas A. P.
AU - Oei, Arlene L.
AU - Kok, H. Petra
AU - Crezee, Johannes
N1 - Funding Information: Funding: This research was funded by the Dutch Cancer Society, UVA grant number 10595. Publisher Copyright: © 2021 by the authors. Licensee MDPI, Basel, Switzerland.
PY - 2021/7/2
Y1 - 2021/7/2
N2 - Hyperthermic intraperitoneal chemotherapy (HIPEC) is a treatment modality for patients with peritoneal metastasis (PM) of various origins which aims for cure in combination with cytoreductive surgery (CRS). Efficacy of CRS-HIPEC depends on patient selection, tumor type, delivery technique, and treatment parameters such as temperature, carrier solution, type of drug, dosage, volume, and treatment duration. Preclinical research offers a powerful tool to investigate the impact of these parameters and to assist in designing potentially more effective treatment protocols and clinical trials. The different methodologies for peritoneal disease and HIPEC are variable. This study aims to review the objectives, methods, and clinical relevance of in vivo preclinical HIPEC studies found in the literature. In this review, recommendations are provided and possible pitfalls are discussed on the choice of type of animal and tumor model per stratified parameters and study goal. The guidelines presented in this paper can improve the clinical relevance and impact of future in vivo HIPEC experiments.
AB - Hyperthermic intraperitoneal chemotherapy (HIPEC) is a treatment modality for patients with peritoneal metastasis (PM) of various origins which aims for cure in combination with cytoreductive surgery (CRS). Efficacy of CRS-HIPEC depends on patient selection, tumor type, delivery technique, and treatment parameters such as temperature, carrier solution, type of drug, dosage, volume, and treatment duration. Preclinical research offers a powerful tool to investigate the impact of these parameters and to assist in designing potentially more effective treatment protocols and clinical trials. The different methodologies for peritoneal disease and HIPEC are variable. This study aims to review the objectives, methods, and clinical relevance of in vivo preclinical HIPEC studies found in the literature. In this review, recommendations are provided and possible pitfalls are discussed on the choice of type of animal and tumor model per stratified parameters and study goal. The guidelines presented in this paper can improve the clinical relevance and impact of future in vivo HIPEC experiments.
KW - Cytoreductive surgery (CRS)
KW - Hyperthermic intraperitoneal chemotherapy (HIPEC)
KW - Peritoneal carcinomatosis
KW - Peritoneal metastasis
UR - http://www.scopus.com/inward/record.url?scp=85109157142&partnerID=8YFLogxK
U2 - https://doi.org/10.3390/cancers13143430
DO - https://doi.org/10.3390/cancers13143430
M3 - Review article
C2 - 34298644
SN - 2072-6694
VL - 13
JO - Cancers
JF - Cancers
IS - 14
M1 - 3430
ER -